Chantal Mathieu, MD, PhD

Chantal Mathieu, MD, PhD

Professor of Medicine
Program Director of Biomedical Sciences
Katholieke Universiteit
Chair of Endocrinology
University Hospital Gasthuisberg
Leuven, Belgium

Related Videos

In your mind what are the implications of the LEADER trial evaluating liraglutide in reducing CV outcomes? Video

In your mind what are the implications of the LEADER trial evaluating liraglutide in reducing CV outcomes?

In your mind what are the implications of the LEADER trial evaluating liraglutide in reducing CV outcomes?

If a clinician is contemplating iDeglira or iGlarlixi in a T2D patient on an oral antidiabetic agent who is not meeting HA1c goals, should the oral medication be adjusted in any way, or discontinued? Video

If a clinician is contemplating iDeglira or iGlarlixi in a T2D patient on an oral antidiabetic agent who is not meeting HA1c goals, should the oral medication be adjusted in any way, or discontinued?

If a clinician is contemplating the use of iDeglira or iGlarlixi in a T2D patient already on an oral antidiabetic agent who is not meeting HA1c goals, should the oral medication be adjusted in any way, or should it be discontinued?

From a practical perspective, how should we deploy the new ultra-long basal insulins and for which patient populations -- T1D and/or T2D -- are they best suited? How are these agents titrated? Video

From a practical perspective, how should we deploy the new ultra-long basal insulins and for which patient populations -- T1D and/or T2D -- are they best suited? How are these agents titrated?

From a practical perspective, how should we deploy the new ultra-long basal insulins and for which patient populations — T1D and/or T2D — are they best suited? How are these agents titrated?

What is the rationale for more concentrated basal insulins -- U200 degludec and U300 insulin glargine -- and what advantages do they offer in glycemic control and hypoglycemia risk? Video

What is the rationale for more concentrated basal insulins -- U200 degludec and U300 insulin glargine -- and what advantages do they offer in glycemic control and hypoglycemia risk?

What is the rationale for deploying more concentrated basal insulins — U200 degludec and U300 insulin glargine — and what advantages do they offer with respect to physiologic glycemic control and hypoglycemia risk?

Based on clinical profiles and metabolic parameters, which patients with T2D are ideally suited for treatment with a fixed ratio, combination of insulin and a GLP-1 RA? Video

Based on clinical profiles and metabolic parameters, which patients with T2D are ideally suited for treatment with a fixed ratio, combination of insulin and a GLP-1 RA?

Based on clinical profiles and metabolic parameters, which patients with T2D are ideally suited for treatment with a fixed ratio, combination of insulin and a GLP-1 RA?

What evidence is available to guide us in adding antiglycemic agents to intensify basal insulin therapy? What is the rationale for using a fixed ratio insulin-GLP- 1 RA combination formulation? Video

What evidence is available to guide us in adding antiglycemic agents to intensify basal insulin therapy? What is the rationale for using a fixed ratio insulin-GLP- 1 RA combination formulation?

What options and evidence are available to guide us in adding antiglycemic agents to intensify basal insulin therapy? What is the role and rationale for using a fixed ratio insulin-GLP- 1 RA combination formulation?